HDAC inhibitors with PD-1 blockade: a promising strategy for treatment of multiple cancer types?

Epigenomics. 2016 Aug;8(8):1015-7. doi: 10.2217/epi-2016-0066. Epub 2016 Jul 13.
No abstract available

Keywords: PD-1; T cells; T-cell chemokines; clinical trial; epigenetic agents; histone deacetylase inhibitors; immunotherapy; lung cancer; romidepsin; vorinostat.

Publication types

  • Editorial
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Depsipeptides / administration & dosage
  • Histone Deacetylase Inhibitors / administration & dosage*
  • Humans
  • Lymphocytes, Tumor-Infiltrating / drug effects
  • Lymphocytes, Tumor-Infiltrating / pathology
  • Mice
  • Molecular Targeted Therapy / methods
  • Molecular Targeted Therapy / trends
  • Neoplasms / classification
  • Neoplasms / drug therapy*
  • Neoplasms / pathology
  • Programmed Cell Death 1 Receptor / antagonists & inhibitors*
  • Tumor Microenvironment / drug effects
  • Tumor Microenvironment / immunology

Substances

  • Depsipeptides
  • Histone Deacetylase Inhibitors
  • PDCD1 protein, human
  • Programmed Cell Death 1 Receptor
  • romidepsin